HOME Top Market Reports Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019

Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019

By: marketsandmarkets.com
Publishing Date: July 2014
Report Code: PH 2557

 

  Speak to Analyst Enquiry Before Buying
 
purchase report
download pdf  request for customisation


The global human insulin market is estimated to reach $42 billion by 2019, at a CAGR of 12.5% from 2014-2019.The market will be driven by rising prevalence of diabetes worldwide, spiralling aging population that increases the incidences of diabetes, growing obese population due to the change in lifestyle, favorable government initiatives, and introduction of pen device that delivers human insulin efficiently and effectively. However, the regulatory environment for approving biotechnology derived drugs is more complex and stringent in U.S. and Europe that will hinder the market growth. High manufacturing complexities and cost associated with the down streaming process will restrict new players to enter in the market.

The introduction of safety pen needles for effective delivery of insulin will enhance the usage of insulin. This is due to the various advantages offered while injecting insulin through safety pen needles comparative to other standard needles. Various advantages areminimizing needlestick injuries, needle anxiety, implementation of regulations against needlestick injuries, and growing awareness regarding the danger of blood-borne pathogen transmission, thereby representing huge market opportunity for insulin producers.

Modern human insulin will gain the largest share of global human insulin market by the end of 2014. Among modern insulin, Apidra, Levemir, and Lantus are the best-selling products and are estimated to grow at a brisk pace in coming years.

North America is the largest contributor to the global market whileAsia is expected to grow at the highest rate. Asia (China, and India), Middle East (Saudi Arabia, Egypt, Qatar, U.A.E), and Latin America (Brazil, Mexico) are also poised to grow at double-digit CAGRs in the coming years.

The key players in the market are Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis(France),Biocon (India), Julphar(U.A.E),Wockhardt (India),SemBioSys (Canada), and GSK (U.K.).

Scope of the Report

The study covers the revenue market of five major classes of human insulin - short acting, intermediate acting, long acting, fast acting, and premixed. Both traditional and modern human insulin have been covered in the study.

The definition of the insulin for the sake of this market study is as follows:

Human insulin for therapeutic use is a non-glycosylated, disulphide-bonded heterodimer of 51 amino acids and has a key role in regulating glucose metabolism. It is an important drug for treating diabetes mellitus, mainly type 1 diabetes. Both biologics (Branded drugs), and biosimilars (Generic version of branded drugs) have been covered in this study.

Particulars

Scope

Geography

  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and RoE)
  • APAC (India, China, Japan, Korea, Australia, and RoA)
  • RoW (Latin America, Middle East, and Africa)

Historical Years

2012-2013

Base Year

2013

Projected Year

2014

Forecast Period

20152019

Revenue Currency

USD ($)

This research report categorizes the global human insulin market into the following segments:

  • By types:
    • Short acting human insulin
    • Intermediate acting human insulin
    • Long acting human insulin
    • Rapid/Fast acting human insulin
    • Premixed human Insulin
  • By Brands:
    • Apidra
    • Actrapid,Mixtard,andInsulatard
    • Humalog
    • Humulin
    • Insuman
    • Lantus
    • Levemir
    • Novomix
    • Novorapid
    • Tresiba
  • By Geography:
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • RoE
    • APAC
      • China
      • India
      • Japan
      • Korea
      • Australia
      • RoA
    • Rest of the World (RoW)
      • LATAM
      • Africa
      • Middle-East

Table of Content            
                      
1 Introduction  (Slide No. - 24)        
    1.1 Objectives of the Study          
    1.2 Report Description          
    1.3 Market Scope          
    1.4 Market Covered          
    1.5 Research Methodology          
          1.5.1 Market Size Estimation         
          1.5.2 Forecasting Model         
    1.6 Key Data From Secondary & Primary Sources          
    1.7 Assumptions          
            
2 Executive Summary (Slide No. - 36)          
            
3 Premium Insights (Slide No. - 42)          
    3.1 Market Overview          
    3.2 Market Snapshot          
    3.3 Market, By Type          
    3.4 Market, By Brand          
    3.5 Market, By Geography          
    3.6 Human Insulin Market, By Region          
            
4 Market Overview  (Slide No. - 50)         
    4.1 Introduction          
    4.2 History           
    4.3 Market Segmentation          
    4.4 Market Dynamics          
          4.4.1 Drivers         
                  4.4.1.1 Increasing Diabetic Population        
                  4.4.1.2 Rapidly Growing Aging Population        
                  4.4.1.3 Growing Prevalence of Lifestyle-Related Disorders Such As Obesity        
                  4.4.1.4 Biologics Going off-Patent to Boost the Market        
                  4.4.1.5 R&D Initiatives Aimed At Developing New Products        
                  4.4.1.6 Favorable Government Initiatives to Drive the Human Insulin Market        
                  4.4.1.7 Growing Demand for Biosimilar Drugs Due to their Cost-Effectiveness        
                  4.4.1.8 Growing Demand for Insulin Analogs        
                  4.4.1.9 Technological Advancements to Propel the Human Insulin Market        
          4.4.2 Restraints         
                  4.4.2.1 High Manufacturing Complexities and Cost of Production to Hinder the Market Growth        
                  4.4.2.2 Stringent Regulatory Requirements to Restrict the Growth of the Human Insulin Market        
          4.4.3 Opportunities         
                  4.4.3.1 Emerging Countries Present Significant Growth Opportunities        
                  4.4.3.2 Pipeline Products offer Huge Growth Opportunities        
          4.4.4 Challenges         
                  4.4.4.1 Requirement of Complex Infrastructure for Manufacturing and Extensive Clinical Trials for Approvals        
    4.5 Winning Imperatives          
          4.5.1 Collaborations and Agreements to Help Players Gain A Competitive Edge         
    4.6 Burning Issues          
          4.6.1 Product Recalls         
            
5 Market Share Analysis  (Slide No. - 67)         
    5.1 Market Share Analysis           
          5.1.1 Global Market Share Analysis         
          5.1.2 Market Share Analysis, By Geography          
                  5.1.2.1 North America        
                  5.1.2.2 Europe        
                  5.1.2.3 Asia-Pacific        
                  5.1.2.4 ROW        
            
6 Pipeline Analysis  (Slide No. - 73)        
    6.1 Pipeline Analysis          
            
7 Human Insulin Market,  By Type  (Slide No. - 78)           
    7.1 Introduction          
    7.2 Traditional Human Insulin          
          7.2.1 Short-Acting Insulin         
          7.2.2 Intermediate-Acting Insulin         
          7.2.3 Premixed Traditional Human Insulin         
    7.3 Modern Human Insulin          
          7.3.1 Rapid-Acting Insulin         
          7.3.2 Long-Acting Insulin         
          7.3.3 Premixed Modern Human Insulin         
            
8 Human Insulin Market,  By Brand   (Slide No. - 98)        
    8.1 Introduction          
    8.2 Traditional Human Insulin Market, By Brand          
          8.2.1 Humulin         
          8.2.2 Actrapid, Mixtard, & Insulatard         
          8.2.3 Humulin         
    8.3 Modern Human Insulin Market, By Brand          
          8.3.1 Lantus         
          8.3.2 Novorapid/Novolog         
          8.3.3 Humalog         
          8.3.4 Levemir         
          8.3.5 Novomix         
          8.3.6 Apidra         
          8.3.7 Tresiba         
            
9 Human Insulin Market,  By Geography  (Slide No. - 115)          
    9.1 Introduction          
    9.2 North America          
          9.2.1 U.S.         
          9.2.2 Canada         
    9.3 Europe          
          9.3.1 U.K.         
          9.3.2 Germany         
          9.3.3 France         
          9.3.4 Italy          
          9.3.5 Spain         
          9.3.6 Roe          
    9.4 Asia-Pacific          
          9.4.1 Japan         
          9.4.2 China         
          9.4.3 India         
          9.4.4 Korea, Australia, and Roa         
    9.5 ROW          
          9.5.1 Middle East          
          9.5.2 Latin America         
          9.5.3 Africa         
           
10 Competitive Landscpe  (Slide No. - 192)      
     10.1 Introduction          
     10.2 New Product Approvals          
     10.3 Collaborations, Agreements, and Joint Ventures          
     10.4 Other Developments          
            
11 Company Profiles  (Slide No. - 201)        
     11.1 Novo Nordisk - Overview          
     11.2 Eli Lilly - Overview          
     11.3 Sanofi - Overview          
     11.4 Biocon - Overview          
     11.5 Julphar - Overview          
            
List of Tables (110 Tables)           

Table 1 Global Market Size, By Product,  20122019 ($Million)           
Table 2 Global Market Size,  2014-2019 (Tmu)           
Table 3 Global Traditional Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 4  Global Traditional Human Insulin Market Size, By Region,  20122019 ($Million)           
Table 5 Global Short-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 6 Global Intermediate-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 7 Global Premixed Traditional Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 8 Global Modern Insulin Market Size, By Type, 20122019 ($Million)           
Table 9 Global Modern Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 10 Global Rapid-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 11 Global Long-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 12 Global Premixed Modern Insulin Market Size, By Region, 20122019 ($Million)           
Table 13 Global Traditional Insulin Market Size, By Brand, 20122019 ($Million)           
Table 14 Global Humulin Market Size, By Region, 20122019 ($Million)           
Table 15 Global Actrapid, Mixtard, & Insulatard Market Size, By Region, 20122019 ($Million)           
Table 16 Global Insuman Market Size,  By Region, 20122019 ($Million)           
Table 17 Global Modern Human Insulin Market Size, By Brand, 20122019 ($Million)           
Table 18 Global Lantus Market Size, By Region, 20122019 ($Million)           
Table 19 Global Novorapid/Novolog Market Size, By Region, 20122019 ($Million)           
Table 20 Global Humalog Market Size, By Region, 20122019 ($Million)           
Table 21 Global Levemir Market Size, By Region, 20122019 ($Million)           
Table 22 Global Novomix Market Size, By Region, 20122019 ($Million)           
Table 23 Global Apidra Market Size, By Region, 20122019 ($Million)           
Table 24 Global Tresiba Market Size, By Region, 20122019 ($Million)           
Table 25 Market Size, By Region, 20122019 ($Million)           
Table 26 Global Market Size, By Country, 20122019 ($Million)           
Table 27 Long-Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 28 Rapid-Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 29 Premixed Modern Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 30 Short-Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 31 Intermediate-Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 32 Premixed Traditional Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 33 North America: Diabetes Prevalence Rate            
Table 34 North America: off-Patent Human Insulin Products            
Table 35 North America: Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 36 North America: Traditional Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 37 North America: Modern Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 38 North America: Traditional Human Insulin Market Size, By Brand, 20122019 ($Million)           
Table 39 North America: Traditional Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 40 North America: Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 41 North America: Modern Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 42 U.S.: Market Size, By Type, 20122019 ($Million)           
Table 43 Canada: Market Size, By Type, 20122019 ($Million)           
Table 44 North America: Short Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 45 North America: Intermediate-Acting Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 46 North America: Premixed Traditional Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 47 North America: Long-Acting Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 48 North America: Rapid-Acting Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 49 North America: Premixed Modern Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 50 Europe: Diabetes Prevalence Rate            
Table 51 Europe : Off-Patent Human Insulin Products             
Table 52 Europe: Market Size, By Type, 20122019 ($Million)           
Table 53 Europe: Traditional Market Size, By Type, 20122019 ($Million)           
Table 54 Europe: Modern Market Size, By Type, 20122019 ($Million)           
Table 55 Europe: Traditional Human Insulin Market Size, By  Brand, 20122019 ($Million)           
Table 56 Europe: Modern Human Insulin Market Size, By  Brand, 20122019 ($Million)           
Table 57 Europe: Traditional Human Insulin Market Size, By  Brand, 20122019 ($Million)           
Table 58 Europe: Modern Human Insulin Market Size, By  Brand, 20122019 ($Million)           
Table 59 Germany: Market Size, By Type, 20122019 ($Million)           
Table 60 France: Market Size, By Type, 2012-2019 ($Million)           
Table 61 U.K.: Market Size, By Type, 20122019 ($Million)           
Table 62 Italy: Market Size, By Type, 20122019 ($Million)           
Table 63 Spain: Market Size, By Type, 20122019 ($Million)           
Table 64 Roe: Market Size, By Type, 20122019 ($Million)           
Table 65 Europe: Short-Acting Traditional Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 66 Europe: Intermediate-Acting Traditional Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 67 Europe: Premixed Traditional Human Insulin Market Size, By Country/Region, 2012-2019 ($Million)           
Table 68 Europe: Long-Acting Modern Human Insulin Market Size, By Country/Region, 20122019 ($Million)           
Table 69 Europe: Rapid-Acting Modern Human Insulin Market Size Size, By Country/Region, 20122019 ($Million)           
Table 70 Europe: Premixed Modern Human Insulin Market Size, By Country/Region, 20122019 ($Million)           
Table 71 Asia-Pacific: Diabetes Prevalence Rate            
Table 72 Asia-Pacific: Off-Patent Human Insulin Products            
Table 73 Asia-Pacific: Market Size, By Type, 20122019 ($Million)           
Table 74 Asia-Pacific: Traditional Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 75 Asia-Pacific: Modern Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 76 Asia-Pacific: Traditional Human Insulin Market Size, By Brand, 20122019 ($Million)           
Table 77 Asia-Pacific: Modern Human Insulin Market Size, By Brand, 20122019 ($Million)           
Table 78 Asia-Pacific: Traditional Human Insulin Market Size, By  Country, 2012-2019 ($Million)           
Table 79 Asia-Pacific: Modern Human Insulin Market Size, By  Country, 2012-2019 ($Million)           
Table 80 China: Market Size, By Type, 20122019 ($Million)           
Table 81 China: Market Size, By Type, 20122019 ($Million)           
Table 82 Japan: Market Size, By Type, 2012-2019 ($Million)           
Table 83 Australia: Market Size, By Type, 2012-2019 ($Million)           
Table 84 Korea: Market Size, By Type, 20122019 ($Million)           
Table 85 Roa: Market Size, By Type, 20122019 ($Million)           
Table 86 Asia-Pacific: Short-Acting Traditional Human Insulin Market Size, By Country, 2012-2019 ($Million)           
Table 87 Asia-Pacific: Short-Acting Traditional Human Insulin Market Size, By Country, 2012-2019 ($Million)           
Table 88 Asia-Pacific: Premixed Traditional Human Insulin Market Size, By Country, 20122019 ($Million)           
Table 89 Asia-Pacific: Long-Acting Modern Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 90 Asia-Pacific: Rapid-Acting Modern Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 91 Asia-Pacific: Premixed Modern Human Insulin Market Size, By  Country, 20122019 ($Million)           
Table 92 ROW: Diabetes Prevalence Rate, 20002030            
Table 93 ROW: Market Size, By Type, 20122019 ($Million)           
Table 94 ROW: Traditional Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 95 ROW: Modern Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 96 ROW: Traditional Human Insulin Market Size, By Brand , 20122019 ($Million)           
Table 97 ROW: Modern Human Insulin Market Size, By Brand, 20122019 ($Million)           
Table 98 ROW: Traditional Human Insulin Market Size, By Region, 2012-2019 ($Million)           
Table 99 ROW: Modern Human Insulin Market Size, By Region, 2012-2019 ($Million)           
Table 100 Latin America: Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 101 Middle East: Human Insulin Market Size, By Type, 20122019 ($Million)           
Table 102 Africa: Market Size, By  Type, 20122019 ($Million)           
Table 103 ROW: Short-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 104 ROW: Intermediate-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 105 ROW: Premixed Traditional Human Insulin Market Size, By Region, 20142019 ($Million)           
Table 106 ROW: Long-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 107 ROW: Rapid-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 108 ROW: Premixed Modern Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 109 New Product Approvals, 20112014           
Table 110 Collaborations, Agreements, and Joint Ventures, 20112014           
Table 111 Other Developments, 20112014           
Table 103 ROW: Short-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 104 ROW: Intermediate-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 105 ROW: Premixed Traditional Human Insulin Market Size, By Region, 20142019 ($Million)           
Table 106 ROW: Long-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 107 ROW: Rapid-Acting Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 108 ROW: Premixed Modern Human Insulin Market Size, By Region, 20122019 ($Million)           
Table 109 New Product Approvals, 20112014           
Table 110 Collaborations, Agreements, and Joint Ventures, 20112014           


List of Figures (55 Figures)           

Figure 1 Research Methodology           
Figure 2 Market Size Estimation Model           
Figure 3 Market Forecasting Model            
Figure 4 Global Market Size, Biologics Vs. Biosimilars, 20142019 ($Million)           
Figure 5 Global Market, Traditional Human Insulin Vs. Modern Human Insulin, 20142019 ($Million)           
Figure 6 Global Market Size, By Brand, 2014-2019 ($Million)           
Figure 7 Market Overview
Figure 8 Market Snapshot, 2014 ,($Million)           
Figure 9 Global Market, By Type of Insulin, 2014 ($Million)           
Figure 10 Opportunity Matrix: Global Market, By Brand, 2014           
Figure 11 Market, Geographic Analysis, By Type, 2014 ($Million)           
Figure 12 Market, By Geography, 2014 & 2019 ($Million)           
Figure 13 Human Insulin Timeline            
Figure 14 Market Segmentation           
Figure 15 Global Market Share Analysis, By Key Player, 2013 ($Million)           
Figure 16 North America: Market Share Analysis, By Key Player, 2013 ($Million)           
Figure 17 Europe: Market Share Analysis, By Key Player, 2013 ($Million)           
Figure 18 Asia-Pacific: Market Share Analysis, By Key Player, 2013 ($Million)           
Figure 19 ROW: Market Share Analysis, By Key Player, 2013 ($Million)           
Figure 20 Insulin in Pipeline, By Company           
Figure 21 Insulin in Pipeline, By Clinical Trial Phases           
Figure 22 Insulin in Phase-I Clinical Trials           
Figure 23 Insulin in Phase-II Clinical Trials           
Figure 24 Insulin in Phase-III Clinical Trials           
Figure 25 Insulin in Phase-IV Clinical Trials           
Figure 26 Global Traditional Human Insulin Market Share, By Type, 2014           
Figure 27 Global Traditional Human Insulin Market Size, By Region,2014 ($Million)           
Figure 28 Global Modern Human Insulin Market Size, By  Type,  2014 Vs. 2019 ($Million)           
Figure 29 Global Modern Human Insulin Market Size, By Region, 2014($Million)           
Figure 30 Global Traditional Human Insulin Market Size, By Brand, 2014 Vs. 2019 ($Million)           
Figure 31 Modern Market Size, By Brand, 2014 Vs. 2019 ($Million)           
Figure 32 Major Potential Markets           
Figure 33 Opportunity Matrix: Market Size, By Region, 2014            
Figure 34 Opportunity Matrix : Global Market, By Country, 2014            
Figure 35 Key Growth Strategies of the Global Market, 20112014            
Figure 36 Geographic Presence (Manufacturing Plants)           
Figure 37 Recent Financials, 2011 2013           
Figure 38 Business Revenue Mix           
Figure 39 Geographic Revenue Mix           
Figure 40 Geographic Presence (Manufacturing Plants)           
Figure 41 Insulin in Phase-Iv Clinical Trials           
Figure 42 Business Revenue Mix (Human Pharmaceutical Products)           
Figure 43 Geographic Revenue Mix           
Figure 44 Geographic Presence (Manufacturing Plants)           
Figure 45 Recent Financials, 2011 2013           
Figure 46 Business Revenue Mix           
Figure 47 Geographic Revenue Mix           
Figure 48 Geographic Presence (Manufacturing Plant)           
Figure 49 Recent Financials, 2011 2013           
Figure 50 Business Revenue Mix           
Figure 51 Geographic Revenue Mix           
Figure 52 Geographic Presence (Manufacturing Plant)           
Figure 53 Recent Financials, 2011 2013           
Figure 54 Business Revenue Mix           
Figure 55 Geographic Revenue Mix

The human insulin market is segmented based on types of insulin, and branded drugs available in the market. The two major classifications of human insulin are traditional and modern human insulin. Further traditional human insulin is divided into three types- short acting, intermediate acting, and premixed traditional insulin. Modern human insulin is fragmented into long acting, rapid acting, and premixed modern insulin. Of all, premixed and long acting modern human insulin will be the two fastest growing markets in the given forecast period.

The biologics/branded insulin considered for this study are Apidra, Actrapid, Humalog, Humulin, Insuman, Insulatard, Lantus, Levemir, Mixtard, Novomix, Novorapid, and Tresiba. The three biosimilars available in the Asian countries and RoW are Wosulin (Wockhardt), Basalog (Biocon), and Glaritus (Wockhardt). In comparison to branded drugs, biosimilar, a similar version of branded biologics, will be the faster growing market in the next five years. Among all available brands, Lantus (Insulin Glargine) accounted for the largest share in the market whereas Apidra and Levemir will be the fastest growing drugs in the forecast period.

The global human insulin market is estimated to reach $42 billion by 2019, at a CAGR of 12.5% from 2014-2019. A major factor that propels the growth of the market is the increasing demand for biologics and biosimilars to treat diabetes. Apart from this, factors such as government initiatives, growing aging population, and high prevalence of diabetes across the globe will foster the demand of insulin. The adoption of new technologies such as safety pen needles offers huge potential opportunity for growth in the market.

The major bottlenecks for the growth of the market are stringent and complex regulatory guidelines that delay the approval process of new drugs as well as high manufacturing complexities and cost associated in the development of human insulin. Further, issues such as contamination while manufacturing insulin by recombinant DNA technology sslow down the yield and production of insulin, thus restricting the market entry.

Countriessuch as China, India, Japan, Singapore, Brazil, Korea, Mexico, and Saudi Arabia represent a lucrative growthopportunity for investors.

The key players in the market are Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis(France),Biocon (India), Julphar(U.A.E),Wockhardt (India),SemBioSys (Canada), and GSK (U.K.).

Global Human Insulin Market Scenario

Human Insulin Market

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports